Moore Capital Management
GBT

Moore Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Moore Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,501
Closed -$676K – 832
2022
Q1 		$676K Buy
+19,501
New +$583K 0.02% 447
2021
Q1 		– Sell
-86,915
Closed -$3.76M – 844
2020
Q4 		$3.76M Sell
86,915
-24,830
-22% -$1.22M 0.04% 294
2020
Q3 		$6.16M Buy
+111,745
New +$7.1M 0.12% 164
2017
Q1 		– Sell
-75,000
Closed -$1.08M – 246
2016
Q4 		$1.08M Buy
+75,000
New +$1.32M 0.04% 146
2016
Q1 		– Sell
-40,000
Closed -$1.29M – 356
2015
Q4 		$1.29M Buy
+40,000
New +$1.73M 0.04% 234

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Moore Capital Management's GBT Position: Q2 2022 in Review

Moore Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 19,501 shares — an estimated $676K sold.

Moore Capital Management first reported a position in GBT in Q4 2015 and held it in 5 quarters. The position peaked at $6.16M in Q3 2020. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Moore Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Moore Capital Management sold 19,501 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $676K.
  • Moore Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 5 quarters.
  • Moore Capital Management's Global Blood Therapeutics, Inc. position peaked at $6.16M in Q3 2020.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Moore Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.